Nonclinical Safety Profile of Revusiran, a 1st-Generation GalNAc-siRNA Conjugate for Treatment of Hereditary Transthyretin-Mediated Amyloidosis

Jessica E. Sutherland, Wendell Davis|Nucleic Acid Therapeutics|2019

Cited by 21